论文部分内容阅读
目的:探讨双歧三联活菌胶囊对溃疡性结肠炎(UC)患者血清超敏C反应蛋白(hs-CRP)及降钙素原(PCT)水平的影响及疗效观察。方法:活动期UC门诊患者96例随机分为观察组和对照组各48例。对照组患者予调整饮食及5-氨基水杨酸1.0 g,po,tid;观察组在此基础上加用双歧三联活菌胶囊630 mg,potid。均连用10周。观察两组治疗前后血清hs-CRP和PCT水平变化,比较临床疗效及药品不良反应。结果:治疗10周后,两组患者血清hs-CRP和PCT水平均较治疗前明显下降(P<0.05和P<0.01),且观察组水平明显低于对照组(P<0.05)。观察组临床总有效率明显优于对照组(P<0.05),两组药品不良反应例数比较,差异无统计学意义(P>0.05)。结论:双歧三联活菌胶囊治疗UC的临床疗效较显著,安全性好,与降低血清hs-CRP和PCT水平,抑制肠黏膜炎症反应过程密切相关。
Objective: To investigate the effect of bifid triplex capsule on serum hs-CRP and procalcitonin (PCT) in patients with ulcerative colitis (UC) and to observe its curative effect. Methods: 96 cases of active stage outpatients were randomly divided into observation group and control group, 48 cases in each group. Control group patients to adjust diet and 5-aminosalicylic acid 1.0 g, po, tid; observation group on this basis with bifidobacterium triple viable capsule 630 mg, potid. All use for 10 weeks. The changes of serum hs-CRP and PCT levels in both groups before and after treatment were observed, and the clinical efficacy and adverse drug reactions were compared. Results: After 10 weeks of treatment, the serum hs-CRP and PCT levels in both groups were significantly lower than those before treatment (P <0.05 and P <0.01), and the levels in the observation group were significantly lower than those in the control group (P <0.05). The clinical total effective rate in the observation group was significantly better than that in the control group (P <0.05). There was no significant difference in the number of adverse drug reactions between the two groups (P> 0.05). CONCLUSION: The clinical efficacy of bifid triple-viable capsule in the treatment of UC is significant and safe. It is closely related to the reduction of serum hs-CRP and PCT levels and the inhibition of intestinal mucosal inflammatory response.